Christie M Ballantyne

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial)
    Christie M Ballantyne
    Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
    Am J Cardiol 111:506-9. 2013
  2. ncbi Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas
    Christie M Ballantyne
    Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas 77030, USA
    J Am Coll Cardiol 52:626-32. 2008
  3. ncbi CD11c expression in adipose tissue and blood and its role in diet-induced obesity
    Huaizhu Wu
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Tex 77030, USA
    Arterioscler Thromb Vasc Biol 30:186-92. 2010
  4. ncbi Preoperative statin therapy decreases risk of postoperative renal insufficiency
    Salim S Virani
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Cardiovasc Ther 28:80-6. 2010
  5. ncbi Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study
    Kelly A Volcik
    Human Genetics Center, University of Texas Health Science Center, Houston, Texas, USA
    Am J Hypertens 21:533-8. 2008
  6. ncbi ApoE and the role of very low density lipoproteins in adipose tissue inflammation
    Jiali Wang
    Division of Atherosclerosis and Vascular Medicine, Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, 6565 Fannin, M S A 601, Houston, TX 77030, USA
    Atherosclerosis 223:342-9. 2012
  7. ncbi Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery disease
    Salim S Virani
    Center of Excellence, Health Services Research and Development, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA
    Circ J 76:950-6. 2012
  8. ncbi Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study
    John W Gaubatz
    Department of Medicine, Baylor College of Medicine, 6565 Fannin St, Houston, TX 77030, USA
    Arterioscler Thromb Vasc Biol 30:1034-42. 2010
  9. ncbi Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients
    Justin Saunders
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Tex, USA
    J Vasc Surg 53:668-75. 2011
  10. ncbi Differential effect of weight loss with low-fat diet or high-fat diet restriction on inflammation in the liver and adipose tissue of mice with diet-induced obesity
    Qun Wang
    Division of Atherosclerosis and Vascular Medicine, Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, 6565 Fannin, M S A 601, Houston, TX 77030, USA
    Atherosclerosis 219:100-8. 2011

Detail Information

Publications122 found, 100 shown here

  1. ncbi Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial)
    Christie M Ballantyne
    Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
    Am J Cardiol 111:506-9. 2013
    ..However, to match LDL cholesterol and ApoB treatment goals in the very-high-risk category, the current non-HDL cholesterol goal should be lowered by 8 to 10 mg/dl...
  2. ncbi Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas
    Christie M Ballantyne
    Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas 77030, USA
    J Am Coll Cardiol 52:626-32. 2008
    ..The purpose of this analysis was to compare concentrations of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apoB) before and during statin therapy...
  3. ncbi CD11c expression in adipose tissue and blood and its role in diet-induced obesity
    Huaizhu Wu
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Tex 77030, USA
    Arterioscler Thromb Vasc Biol 30:186-92. 2010
    ..To examine CD11c, a beta(2)-integrin, on adipose tissue (AT) leukocytes and blood monocytes and its role in diet-induced obesity...
  4. ncbi Preoperative statin therapy decreases risk of postoperative renal insufficiency
    Salim S Virani
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Cardiovasc Ther 28:80-6. 2010
    ..Although current guidelines recommend withholding statins in perioperative patients, little information is available on whether perioperative statin use increases risk for postoperative renal failure...
  5. ncbi Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study
    Kelly A Volcik
    Human Genetics Center, University of Texas Health Science Center, Houston, Texas, USA
    Am J Hypertens 21:533-8. 2008
    ....
  6. ncbi ApoE and the role of very low density lipoproteins in adipose tissue inflammation
    Jiali Wang
    Division of Atherosclerosis and Vascular Medicine, Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, 6565 Fannin, M S A 601, Houston, TX 77030, USA
    Atherosclerosis 223:342-9. 2012
    ..To identify the role of triglyceride-rich lipoproteins (TGRLs) and apoE, a major apolipoprotein in TGRLs, in adipose tissue inflammation with high-fat diet (HFD)-induced obesity...
  7. ncbi Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery disease
    Salim S Virani
    Center of Excellence, Health Services Research and Development, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA
    Circ J 76:950-6. 2012
    ....
  8. ncbi Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study
    John W Gaubatz
    Department of Medicine, Baylor College of Medicine, 6565 Fannin St, Houston, TX 77030, USA
    Arterioscler Thromb Vasc Biol 30:1034-42. 2010
    ....
  9. ncbi Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients
    Justin Saunders
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Tex, USA
    J Vasc Surg 53:668-75. 2011
    ....
  10. ncbi Differential effect of weight loss with low-fat diet or high-fat diet restriction on inflammation in the liver and adipose tissue of mice with diet-induced obesity
    Qun Wang
    Division of Atherosclerosis and Vascular Medicine, Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, 6565 Fannin, M S A 601, Houston, TX 77030, USA
    Atherosclerosis 219:100-8. 2011
    ..We studied the effects of weight loss induced by either a low-fat normal diet (ND) or restriction of high-fat diet (HFD) on hepatic steatosis, inflammation in the liver and adipose tissue (AT), and blood monocytes of obese mice...
  11. ncbi T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity
    Huaizhu Wu
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, 6565 Fannin, Houston, TX 77030, USA
    Circulation 115:1029-38. 2007
    ..T cells also play important roles in chronic inflammatory diseases such as atherosclerosis but have not been well studied in obesity...
  12. ncbi Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study
    Salim S Virani
    Michael E DeBakey Veterans Affairs Medical Center Health Services Research and Development Center of Excellence, Houston, TX, USA
    Circulation 125:241-9. 2012
    ..We evaluated associations between Lp(a) and incident CVD events in blacks and whites in the Atherosclerosis Risk in Communities (ARIC) study...
  13. ncbi Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
    Christie M Ballantyne
    Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Tex 77030, USA
    Arch Intern Med 165:2479-84. 2005
    ..We assessed Lp-PLA2 and C-reactive protein (CRP) levels along with traditional risk factors to examine their relation to ischemic stroke...
  14. ncbi Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study
    Vijay Nambi
    Department of Medicine, Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Stroke 40:376-81. 2009
    ....
  15. ncbi Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II
    Christie M Ballantyne
    Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, TX, USA
    Am Heart J 151:975.e1-9. 2006
    ..This target can be difficult to attain with diet and current therapy...
  16. ncbi Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    J Am Coll Cardiol 55:1600-7. 2010
    ..We evaluated whether carotid intima-media thickness (CIMT) and the presence or absence of plaque improved coronary heart disease (CHD) risk prediction when added to traditional risk factors (TRF)...
  17. ncbi Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity
    Qun Wang
    Department of Medicine, Section of Cardiovascular Research, Baylor College of Medicine, Houston, Texas, USA
    Obesity (Silver Spring) 19:505-13. 2011
    ..Thus, rimonabant induced weight loss in obese mice by diet-intake-dependent and -independent fashions. Rimonabant decreased inflammation in obese mice, possibly through a primary effect on weight reduction...
  18. ncbi Inflammatory protein levels and depression screening after coronary stenting predict major adverse coronary events
    Lorraine Frazier
    School of Nursing, Texas Heart Institute at St Luke s Episcopal Hospital, Houston, Texas 77030, USA
    Biol Res Nurs 11:163-73. 2009
    ..We examined levels of inflammatory proteins to be possible predictors of future MACE and physiological and psychological factors that initiate temporal increases in inflammatory protein levels...
  19. ncbi Usefulness of single nucleotide polymorphism in chromosome 4q25 to predict in-hospital and long-term development of atrial fibrillation and survival in patients undergoing coronary artery bypass grafting
    Salim S Virani
    Michael E DeBakey Veterans Affairs Medical Center Health Services Research and Development Center of Excellence, Houston, Texas, USA
    Am J Cardiol 107:1504-9. 2011
    ....
  20. ncbi Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia
    Christie M Ballantyne
    Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 93:1487-94. 2004
    ..5%; p <0.001). All treatments were well tolerated. Thus, a greater LDL cholesterol decrease and HDL cholesterol increase were attained by treating patients with co-administration of ezetimibe and simvastatin than with atorvastatin...
  21. ncbi Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides
    Christie M Ballantyne
    Baylor College of Medicine, Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA
    Cardiovasc Drugs Ther 25:59-67. 2011
    ..The objective of this study was to evaluate the long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients at goal for low-density lipoprotein cholesterol (LDL-C) but with persistent hypertriglyceridemia...
  22. ncbi Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study
    Justin T Saunders
    6565 Fannin, MS A 601, Houston, TX 77030, USA
    Circulation 123:1367-76. 2011
    ....
  23. ncbi Obesity: an independent predictor of in-hospital postoperative renal insufficiency among patients undergoing cardiac surgery?
    Salim S Virani
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Tex Heart Inst J 36:540-5. 2009
    ....
  24. ncbi Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system
    Mine Y Liu
    Section of Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Chem 51:1102-9. 2005
    ....
  25. ncbi Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: the atherosclerosis risk in communities study
    Kelly Volcik
    University of Texas Health Science Center, School of Public Health, Human Genetics Center, 1200 Hermann Pressler, Houston, Texas 77030, USA
    J Stud Alcohol Drugs 68:485-92. 2007
    ..Genes of interest included cholesterol ester transfer protein (CETP), lipoprotein lipase (LPL), hepatic lipase (HL), and paraoxonase-1 (PON1)...
  26. ncbi Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study
    Salim S Virani
    Michael E DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA
    Eur Heart J 32:459-68. 2011
    ..To assess the relationship between regulated on activation, normal T-cell expressed and secreted (RANTES) and carotid atherosclerotic plaque burden and plaque characteristics...
  27. ncbi Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis
    Suet Nee Chen
    Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center and Texas Heart Institute, Houston, TX, USA
    BMC Med Genet 10:111. 2009
    ....
  28. ncbi P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study
    Kelly A Volcik
    Human Genetics Center, University of Texas Houston Health Science Center, 1200 Herman Pressler Dr, Houston, TX 77030, USA
    Atherosclerosis 186:74-9. 2006
    ....
  29. ncbi Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
    Ariel Brautbar
    Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Atherosclerosis 219:737-42. 2011
    ..We sought to identify single nucleotide polymorphisms (SNPs) associated with HDL-C, TG, and apolipoprotein A1 (ApoA-I) response to combination therapy with statins and fenofibric acid (FA) in individuals with atherogenic dyslipidemia...
  30. ncbi Outcomes of preoperative angiotensin-converting enzyme inhibitor therapy in patients undergoing isolated coronary artery bypass grafting
    Salman J Bandeali
    Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 110:919-23. 2012
    ..In conclusion, preoperative ACE inhibitor use was associated with an increased risk of MAEs after CABG, in particular postoperative renal dysfunction and atrial fibrillation...
  31. ncbi Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players
    Salim S Virani
    Health Services Research and Development, Michael E DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX 77030, USA
    Atherosclerosis 222:551-6. 2012
    ....
  32. ncbi The 9p21 genetic variant is additive to carotid intima media thickness and plaque in improving coronary heart disease risk prediction in white participants of the Atherosclerosis Risk in Communities (ARIC) Study
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX, USA
    Atherosclerosis 222:135-7. 2012
    ..We evaluated whether the addition of carotid intima media thickness and plaque (CIMT-P), and a single nucleotide polymorphism on chromosome 9p21 (9p21) together improve coronary heart disease (CHD) risk prediction in the ARIC study...
  33. ncbi The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis
    Suet Nee Chen
    Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, and Texas Heart Institute, Houston, TX 77030, USA
    BMC Cardiovasc Disord 9:3. 2009
    ..The LCAS is a randomized placebo-control longitudinal follow-up study in patients with CAD conducted to test the effects of fluvastatin on progression or regression of coronary atherosclerosis...
  34. ncbi Isolated coronary artery bypass grafting in obese individuals: a propensity matched analysis of outcomes
    Mahboob Alam
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Circ J 75:1378-85. 2011
    ..There is conflicting data regarding the impact of obesity on morbidity and mortality in patients undergoing isolated coronary artery bypass grafting (CABG)...
  35. ncbi Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study
    Ariel Brautbar
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
    Circ Cardiovasc Genet 2:279-85. 2009
    ....
  36. ncbi Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity
    Geeta D Thakker
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Obesity (Silver Spring) 16:2593-600. 2008
    ..Maladaptive metabolic changes of FA metabolism contribute to enhanced myocardial injury in diet-induced obesity...
  37. ncbi A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis
    Suet N Chen
    Section of Cardiology, Center for Preventive Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    J Am Coll Cardiol 45:1611-9. 2005
    ....
  38. ncbi Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study
    Eric Y Yang
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas, USA
    J Am Coll Cardiol 54:2388-95. 2009
    ....
  39. ncbi Barriers to non-HDL cholesterol goal attainment by providers
    Salim S Virani
    Health Policy and Quality Program, Michael E DeBakey VA Medical Center, Health Services Research and Development Center of Excellence and Section of Health Services Research, Baylor College of Medicine, Houston, TX 77030, USA
    Am J Med 124:876-80.e2. 2011
    ..This study assessed providers' knowledge of, attitude toward, and practice regarding non-HDL-C...
  40. ncbi Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study
    Christie M Ballantyne
    Department of Medicine, Baylor College of Medicine, Houston, Tex, USA
    Am Heart J 149:464-73. 2005
    ..Ezetimibe/simvastatin is a highly efficacious, well-tolerated treatment option for hypercholesterolemic patients...
  41. ncbi Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study
    Kelly A Volcik
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Am J Clin Nutr 87:1926-31. 2008
    ..The binding of polyunsaturated fatty acids (PUFAs) to PPARA results in rapid changes in the expression of genes involved in lipid oxidation, with long-chain n-3 fatty acids being potent activators of PPARA...
  42. ncbi Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Tex Heart Inst J 35:388-94. 2008
    ....
  43. ncbi Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)
    Christie M Ballantyne
    Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 99:673-80. 2007
    ..In conclusion, rosuvastatin plus ezetimibe may improve the management of high-risk patients who cannot achieve goal on maximal statin monotherapy...
  44. ncbi Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome
    Christie M Ballantyne
    Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 91:25C-27C; discussion 28C. 2003
    ..Among patients who met the metabolic syndrome criteria and who had triglycerides > or =200 mg/dL, 64% met their ATP III non-HDL goals...
  45. ncbi Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study
    L Maria Belalcazar
    Department of Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Diabetes Care 33:197-9. 2010
    ..To examine usual marine omega-3 fatty acid (mO-3FA) intake in individuals with diabetes; its association with adiposity, lipid, and glucose control; and its changes with behavioral lifestyle intervention for weight loss...
  46. ncbi A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study
    L Maria Belalcazar
    Department of Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Diabetes Care 33:2297-303. 2010
    ....
  47. ncbi Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Eur Heart J 33:183-90. 2012
    ..We evaluated whether CCA-IMT is comparable to A-CIMT when added to TRF and plaque information in improving CHD risk prediction in the Atherosclerosis Risk in Communities (ARIC) study...
  48. ncbi Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu
    Christie M Ballantyne
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX 70030, USA
    J Clin Lipidol 5:401-7. 2011
    ..Combination therapy with a statin and a fibrate may be more effective than statin monotherapy for reducing hsCRP, especially in patients with mixed dyslipidemia...
  49. ncbi Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus
    LaDale St Clair
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 99:80B-88B. 2007
    ....
  50. ncbi Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants
    Kelly A Volcik
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Am J Epidemiol 164:342-8. 2006
    ..The ApoE epsilon2 and epsilon4 alleles were associated with carotid IMT measures in both racial groups, but, after adjusting for lipid parameters, only the epsilon4 allele was associated with carotid IMT measures in African Americans...
  51. ncbi Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial
    Christie M Ballantyne
    Methodist DeBakey Heart Center, Houston, Texas, USA
    Clin Ther 26:1855-64. 2004
    ..Patients with severe hypercholesterolemia may need greater cholesterol reductions than can be achieved with statin therapy alone...
  52. ncbi Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial
    Christie M Ballantyne
    Baylor College of Medicine, 6565 Fannin Street, MS A 601, Houston, Tex 77030, USA
    Circulation 107:2409-15. 2003
    ..Contributing factors may be inadequate dosing, increased risk for adverse effects with high-dose monotherapy, and increased potential for intolerance and adverse effects with combinations of available agents...
  53. ncbi Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging
    Gareth J Adams
    Structural and Computational Biology and Molecular Biophysics Program, Baylor College of Medicine, Houston, TX, USA
    Magn Reson Imaging 22:1249-58. 2004
    ..MRI tracking of changes in atherosclerotic plaques should prove useful in assessing vascular disease risk and monitoring the efficacy of interventions designed to induce regression or retard progression...
  54. ncbi Eotaxin and obesity
    Abu R Vasudevan
    Division of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 91:256-61. 2006
    ..Diet-induced weight loss in humans led to reduction in plasma eotaxin levels, demonstrating that clinical interventions that target obesity can modulate systemic eotaxin levels...
  55. ncbi Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study
    Smita I Negi
    Section of Cardiovascular Research, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX, USA
    Diabetes Care 35:1513-8. 2012
    ..However, so far this association has been shown only in predominantly white populations. We examined IL-18 levels and their association with incident DM in a racially heterogeneous population...
  56. ncbi Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training
    Smita I Negi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    J Clin Lipidol 6:50-7. 2012
    ..Non-high density lipoprotein cholesterol (non-HDL-C) goal attainment per Adult Treatment Panel III (ATP III) guidelines remains low...
  57. ncbi The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk
    Vincent E Friedewald
    Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA
    Am J Cardiol 102:559-67. 2008
  58. ncbi Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS)
    Christie M Ballantyne
    Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 146:862-9. 2003
    ..Previous studies have shown that effects on high-density lipoprotein cholesterol (HDL-C) may differ among statins...
  59. ncbi Does preoperative statin therapy improve outcomes in patients undergoing isolated cardiac valve surgery?
    Salim S Virani
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 102:1235-9. 2008
    ..In conclusion, preoperative statin therapy was not associated with a decrease in morbidity or mortality in patients undergoing isolated cardiac valve surgery...
  60. ncbi Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden
    Christie M Ballantyne
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Tex 77030, USA
    Circulation 117:2458-66. 2008
    ..Intravascular ultrasound showed atheroma volume regression in a single coronary artery with <50% angiographic luminal narrowing...
  61. ncbi Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)
    Christie M Ballantyne
    Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
    Am J Cardiol 101:1428-36. 2008
    ..In conclusion, this study showed that NER/S provided additional clinically relevant improvements in multiple lipid parameters and was safe and well tolerated...
  62. ncbi Role of biomarkers in developing new therapies for vascular disease
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, 6565 Fannin, M S A 601, Houston, Texas 77030, USA
    World J Surg 31:676-81. 2007
    ..These biomarkers may be used to identify specific populations that may benefit from therapies, as surrogate markers of clinical efficacy, or as targets of therapy...
  63. ncbi Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk
    Vijay Nambi
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Curr Atheroscler Rep 7:22-8. 2005
    ..The utility of CRP as a target of therapy remains to be proved, and these ongoing studies will likely provide us with guidance...
  64. ncbi Markers of inflammation and their clinical significance
    Christie M Ballantyne
    Section of Atherosclerosis and Lipoprotein Research, Baylor College of Medicine, 6565 Fannin, M S A 601, Houston, TX 77030 3498, USA
    Atheroscler Suppl 6:21-9. 2005
    ....
  65. ncbi Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus
    Abu R Vasudevan
    Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cornerstone 7:7-16. 2005
    ....
  66. ncbi Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Texas, USA
    Am J Cardiol 96:14K-19K; discussion 34K-35K. 2005
    ..Clinical trials are needed to determine which treatment strategies provide optimal cardiovascular risk reduction...
  67. ncbi Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study
    Ron C Hoogeveen
    Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, 6565 Fannin, M S F 701, Houston, TX 77030, USA
    Atherosclerosis 183:301-7. 2005
    ..These data show that MCP-1 is associated with atherosclerotic disease in two vascular beds and suggest that MCP-1 may be a novel target for atherosclerosis therapy...
  68. ncbi Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia
    Antonios M Xydakis
    Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, 6565 Fannin Street, Houston, TX 77030, USA
    Am J Cardiol 94:795-7. 2004
    ..03), without significantly changing high-density lipoprotein cholesterol, and the combination was well tolerated...
  69. ncbi Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Crit Pathw Cardiol 6:41-5. 2007
    ..More effective management of patients with metabolic syndrome to prevent diabetes and cardiovascular disease will require more effective therapies that target the underlying cause...
  70. ncbi Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events
    Vijay Nambi
    Section of Cardiology, Baylor College of Medicine, 6550 Fannin, SM 677, Houston, TX 77030, USA
    Curr Atheroscler Rep 8:374-81. 2006
    ..Statin therapy has been shown to reduce Lp-PLA(2), and selective inhibitors of Lp-PLA(2) are under development. Additional research is needed to further determine the role of Lp-PLA(2) in atherogenesis and atherothrombotic events...
  71. ncbi Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction
    Christie M Ballantyne
    aBaylor College of Medicine and the Methodist DeBakey Heart Center, Houston, Tex 77030, USA
    Am Heart J 148:S3-8. 2004
    ..More effective lipid-lowering therapy than that currently practiced may be needed in many patients to achieve optimal CHD risk reduction...
  72. ncbi How to identify patients with vulnerable plaques
    Salim S Virani
    Section of Cardiology, Baylor College of Medicine and Texas Heart Institute, St Luke s Episcopal Hospital, Houston, TX, USA
    Diabetes Obes Metab 10:824-33. 2008
    ....
  73. ncbi Relationship of alcohol consumption and type of alcoholic beverage consumed with plasma lipid levels: differences between Whites and African Americans of the ARIC study
    Kelly A Volcik
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Ann Epidemiol 18:101-7. 2008
    ..The influence of different types of alcoholic beverages on plasma lipid levels has been investigated to a lesser extent and in limited populations...
  74. ncbi Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study
    Salim S Virani
    Michael E DeBakey Veterans Affairs Medical Center, Houston, TX 77030, United States
    Atherosclerosis 219:596-602. 2011
    ....
  75. ncbi Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD)
    Vijay Nambi
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Platelets 20:199-205. 2009
    ..Although the mechanism for these observed differences are not clear, we hypothesize that in vivo platelet activation in PAD patients may contribute to the differences and will need to be further investigated...
  76. ncbi Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction
    Antonios M Xydakis
    Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 89:2697-703. 2004
    ..Thus, increases in plasma levels of adiponectin or reductions in TNF-alpha are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss...
  77. ncbi Pharmacological strategies for lowering LDL cholesterol: statins and beyond
    Ariel Brautbar
    Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Methodist DeBakey Heart and Vascular Center, 6565 Fannin, M S A 601, Houston, TX 77030, USA
    Nat Rev Cardiol 8:253-65. 2011
    ..These agents could be particularly appropriate for patients with severely elevated LDL-C levels, such as those with genetic dyslipidemia, for whom maximal drug therapy is insufficient to reduce LDL-C concentrations to recommended levels...
  78. ncbi PLAC test for identification of individuals at increased risk for coronary heart disease
    Ron C Hoogeveen
    Baylor College of Medicine, Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Center for Cardiovascular Disease Prevention, Houston, TX 77030, USA
    Expert Rev Mol Diagn 5:9-14. 2005
    ..More specifically, the article addresses the potential target group most likely to benefit from this new screening test and provides a prospective scenario for its implementation...
  79. ncbi Efficacy and tolerability of multidrug therapy for hypertriglyceridemia
    Venkateshwar R Polsani
    Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, 6565 Fannin, M S A 601, Houston, TX 77030, USA and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX
    J Clin Lipidol 3:341-4. 2009
    ..Although there is clinical evidence for the safety and efficacy of single-drug therapy and some two-drug combinations for the treatment of hypertriglyceridemia, information is limited on the use of more than 2 drugs...
  80. ncbi Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction
    Geeta D Thakker
    Dept. of Medicine, Baylor College of Medicine, 6565 Fannin, M.S. A-601, Houston, TX 77030, USA
    Am J Physiol Heart Circ Physiol 291:H2504-14. 2006
    ....
  81. ncbi Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cornerstone 8:S6-13. 2007
    ..Weight loss has also been shown to improve risk factors associated with metabolic syndrome...
  82. ncbi Combination therapy with statins and omega-3 fatty acids
    Vijay Nambi
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 98:34i-38i. 2006
    ....
  83. ncbi Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial
    Ashok Balasubramanyam
    Translational Metabolism Unit, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:2236-47. 2011
    ..HIV patients on antiretroviral therapy (ART) have a unique dyslipidemia [elevated triglycerides and non-high-density lipoprotein-cholesterol (HDL-C), low HDL-C] with insulin resistance (characterized by hypoadiponectinemia)...
  84. ncbi Automatic quantification of muscle volumes in magnetic resonance imaging scans of the lower extremities
    Gerd Brunner
    Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Magn Reson Imaging 29:1065-75. 2011
    ..Experiments for the fully automatic detection of muscle volume in MRI scans demonstrated an averaged accuracy, sensitivity and specificity for leave-one-out cross-validation of 88.3%, 93.6% and 87.2%, respectively...
  85. ncbi Strategies for optimizing lipid management
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, TX 77030, USA
    Postgrad Med 116:13-20. 2004
    ..Identification of optimal lipid targets and increased efforts to achieve those targets may help reduce the cardiovascular risk that remains despite lipid-lowering therapy that is currently considered adequate or even aggressive...
  86. ncbi Fluvastatin reduces cardiac mortality in patients with coronary heart disease
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Cardiovasc Drugs Ther 18:67-75. 2004
    ..To test the effectiveness of fluvastatin, 40-80 mg, in reducing the occurrence of cardiac and all-cause mortality in patients with coronary heart disease (CHD)...
  87. ncbi Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 92:3K-9K. 2003
    ..New statins, such as rosuvastatin, offer the prospect of improved lipid-lowering therapy...
  88. ncbi Role of lipid and lipoprotein profiles in risk assessment and therapy
    Christie M Ballantyne
    Section of Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 146:227-33. 2003
    ..Therapies with beneficial effects across the lipid profile would be expected to improve CHD risk reduction...
  89. ncbi Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery
    Salim S Virani
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Am Heart J 155:541-6. 2008
    ..We investigated whether preoperative statin therapy was associated with decreased incidence of postoperative AF in patients undergoing cardiac surgery, including isolated valve surgery and patients with low ejection fraction (EF)...
  90. ncbi Risk for myopathy with statin therapy in high-risk patients
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Baylor College of Medicine, 6565 Fannin, Mail Station A601, Suite A656, Houston, TX 77030, USA
    Arch Intern Med 163:553-64. 2003
    ..Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease...
  91. ncbi Management of metabolic syndrome: statins
    Antonios M Xydakis
    Division of Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Endocrinol Metab Clin North Am 33:509-23, vi. 2004
    ..This article discusses the current evidence supporting the use of statins and their beneficial impact on lipid and nonlipid aspects of metabolic syndrome-related pathology...
  92. ncbi ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients
    Vijay Nambi
    Department of Medicine, Baylor College of Medicine, 6565 Fannin, MS A-601, Houston, TX 77030, USA
    Curr Atheroscler Rep 6:353-8. 2004
    ..These results suggest that all hypertensive patients with additional risk factors should receive lipid-regulating statin therapy to prevent CAD events...
  93. ncbi The editor's roundtable: atherosclerosis regression
    Vincent E Friedewald
    Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, TX, USA
    Am J Cardiol 101:967-74. 2008
  94. ncbi Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease
    Kenneth K Wu
    Vascular Biology Research Center and Department of Internal Medicine, University of Texas Houston Health Science Center, Houston, Tex, USA
    Circulation 107:1729-32. 2003
    ..A high sICAM level increases the risk of CHD, whereas a high level of sTM has a lower risk of CHD. It was unclear whether there was an interaction between sTM and sICAM...
  95. ncbi Statins and inflammatory markers
    Christopher C Case
    Baylor College of Medicine, 6565 Fannin, M.S. A-601, Houston, TX 77030, USA
    Curr Atheroscler Rep 4:42-7. 2002
    ..In this article, we briefly review the biology, epidemiology, and clinical trial data on the effects of statins on some of the more promising inflammatory markers...
  96. ncbi Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials
    Antonios M Xydakis
    Division of Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Opin Cardiol 18:503-9. 2003
    ..Statin therapy, which has already been demonstrated to decrease cardiovascular morbidity and mortality, provides significant reductions in non-high-density lipoprotein cholesterol...
  97. ncbi Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol
    Christopher C Case
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 91:1134-6. 2003
  98. ncbi Combination therapy for combined dyslipidemia
    Antonios M Xydakis
    Division of Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 90:21K-29K. 2002
    ..Clinical trials are needed to determine the optimal treatment in patients with combined dyslipidemia...
  99. ncbi Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
    Christie M Ballantyne
    Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and Methodist DeBakey Heart Center, Houston, Tex 77030, USA
    Circulation 109:837-42. 2004
    ..Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme associated primarily with LDL...
  100. ncbi Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease
    Dennis W Schneck
    AstraZeneca LP, Wilmington, Delaware 19850 5437, USA
    Am J Cardiol 91:33-41. 2003
    ..Significantly greater triglyceride decreases were seen at 80 mg with atorvastatin over rosuvastatin. Both rosuvastatin and atorvastatin were well tolerated over 6 weeks...
  101. ncbi Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome
    Donald B Hunninghake
    Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota, USA
    Clin Ther 25:1670-86. 2003
    ..However, although atorvastatin produced slightly larger decreases in TG, simvastatin produced larger increases in HDL-C...